Attached files
| file | filename |
|---|---|
| EX-10.1 - Avantogen Oncology, Inc. | v162549_ex10-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
October
2, 2009
Date of
Report (Date of earliest event reported)
Avantogen
Oncology, Inc.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
33-55254-28
|
87-0438641
|
|
(State
or Other Jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
|
of
Incorporation)
|
Identification
Number)
|
530 South
Lake Avenue, #363, Pasadena, CA 91101
(Address
of Principal Executive Offices) (Zip Code)
917-969-4681
(Registrant’s
telephone number, including area code)
2121
Avenue of the Stars, Suite 2550, Los Angeles, California 90067
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17
CFR240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Section 8
- Other Events
Item
8.01. Other Events.
On
October 2, 2009, the Company’s licensing partner, SciClone
Pharmaceuticals, Inc. (“SciClone”)
announced the discontinuation of the randomized, placebo-controlled,
double-blind Phase 2 trial that evaluated RP101—a nucleoside analog known as
BVdU—for the treatment of late-stage pancreatic cancer. The Company
is currently evaluating next steps, pending a detailed review and analysis of
safety and efficacy once data are unblinded from SciClone. A press
release of the parent company of Avantogen Oncology, Inc., Acuvax, Inc., is
attached as Exhibit 10.1.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
|
Exhibit
|
|
10.1
|
|
Press
Release of Acuvax, Inc./Avantogen Oncology, Inc. dated October 5,
2009
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Avantogen
Oncology, Inc.
|
|
By:
/s/ William Ardrey
|
|
William
Ardrey
|
|
Chief
Executive Officer
|
Date:
October 9, 2009
EXHIBIT
INDEX
|
Exhibit No.
|
|
Exhibit
|
|
10.1
|
|
Press
Release of Acuvax, Inc./Avantogen Oncology, Inc. dated October 5,
2009
|